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Respiratory Effects in Toluene Diisocyanate
Manufacture: A Multidisciplinary Approach
by Hans Weill,* John Salvaggio,$ Arthur Neilson,* Brian Butcher,*
and Morton Ziskind*
A new plant manufacturing toluene diisocyanate (TDI) has provided a unique oppor-
tunity to investigate the effects of TDI vapor inhalation on respiratory health in a
group of exposed workers who have been studied prior to the start of plant operation.
In order to establish dose-response relationships and determine host factors, complete
biologic monitoring, including pulmonary function and immunologic studies, has been
performed concurrently with a comprehensive environmental monitoring program in-
cluding continuous sampling for atmospheric concentrations of TDI. Study groups
include workers with regular exposure to TDI in production jobs (83), workers with
intermittent contact with this vapor, usually in maintenance (28), and a control group
of workers employed outside the TDI area (55). This population is being followed for
a period of 5 yr.
The plant began operations in August 1973 with start-up procedures completed by
the end of October. TDI spills occurred for numerous reasons, usually attributed to pump
failure and resultant line blockage. Significant exposures also occurred in the drumming
operation. The influence of these malfunctions is noted in the continuous monitoring
data on atmospheric TDI concentrations which continue to reveal frequent excursions
above the threshold limit value (TLV) of 0.02 ppm ceiling. These data are presented in
relation to time and plant location.
Although the first full year follow-up following initial exposure was not complete,
certain preliminary clinical observations were made. A number of workers had episodes
of acute respiratory symptoms related to single exposure to an irritant gas at work,
usually either TDI or phosgene. It appears that two or three workers in the study
population have become "clinically sensitized" to TDI and have been removed from
regular TDI exposure. To date, the total number of workers who report the presence
of recurring respiratory symptoms has not increased in comparison with the pre-exposure
survey.
Pulmonary function data after one full year of TDI exposure are not yet available.
Pre- and post-shift ventilatory function studies do not indicate significant differences
between the exposed and control groups. Selected individuals had carefully controlled
inhalation challenge tests to monitored concentrations of TDI vapor under laboratory
conditions. In workers suspected of having become "sensitized", immediate and/or late
air flow obstruction was demonstrated and could be related to dose of inhaled TDI.
Although it has been recognized for over 20 turing or polyurethane foam operations, com-
years that an asthmatic or bronchitic response prehensive investigations designed to provide
may be detected in workers exposed to toluene correlation of clinical, physiologic, immunologic
diisocyanate (TDI) vapor, either in manufac- and environmental data, have not thus far
been attempted. A new plant manufacturing
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start of plant operation. The objectives of this
investigation are to characterize the pulmonary
physiologic impairment of affected workers;
determine the type of immune response and
host factors associated with clinical manifesta-
tions; and describe the environmental exposure
conditions in terms of TDI atmospheric con-
centrations at the job site. Factors to be con-
sidered in the investigation of occupational
asthma include: environmental characteriza-
tion, measurement of an adverse biologic re-
sponse, mechanism of action, and host factors.
As can be readily appreciated, a multidiscipli-
nary approach is required in order to generate
the component data. Industrial hygiene air
sampling methods are used to characterize
accurately the occupational environment of the
worker. Modern methods for assessing the
adverse biologic response of the lungs include
not only the responses to an interviewer-
administered questionnaire but also sophisti-
cated pulmonary function techniques. Informa-
tion regarding the inhalant environment and
effect on respiratory health can be used to
establish dose-response relationships as well as
determination of a no-effect or threshold level
for the atmospheric contaminant under study.
The mechanism of action and possible pertinent
host factors provide further information which
is of obvious scientific importance as well as
leading to the possibility of preventing the
occupational disease, e.g., screening of poten-
tially susceptible individuals. All of these tech-
niques are being utilized in this study of
workers exposed to TDI vapor in the manu-
facturing process.
Materials and Methods
Plant Environment
A new plant for the production of TDI was
constructed in a pre-existing chemical manu-
facturing complex in Southwestern Louisiana.
TDI operations began in August 1973, and
start-up was considered complete by the end
of October. The major areas within the TDI
plant are: TDI synthesis and process loading;
second-stage transfer or pumping station ;
finishing columns and TDI pump-out; and
drumming. Since operations began, a number
of TDI spills have occurred and these have not
been limited to the start-up period. The spills
have occurred for numerous reasons but are
usually attributed to pump failure and resultant
line blockage. Significant exposures have also
occurred in the drumming operation.
Continuous 24-hr area sampling for TDI is
being accomplished by use of UEI TDI detec-
tors. These instruments continuously monitor
atmospheric TDI concentrations up to 0.08 ppm.
Sensitivity and specificity for TDI are obtained
by utilizing a continuous reel of chemically
impregnated paper tape supplied in cassettes
which run for one week. In operation, air is
drawn through the tape at a flow of 500 ml/
min as it moves past an exposure orifice. If
TDI is present, a stain is developed on the tape,
the intensity being proportional to the concen-
tration of TDI. The exposed tape then moves
past two photo detectors, one measuring re-
flected light from the unexposed half. The two
signals are then compared electronically and
the output is proportional to the TDI concen-
tration. The units have been calibrated in both
the laboratory and under field conditions and
correlate well with the Marcali method (Figs.
1 and 2). The detectors have been moved fre-
quently so that all areas of the plant have been
sampled.
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FIGURE 1. Laboratory calibration of TDI detector.
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FIGURE 2. Field calibration of TDI detector.
Study Population
A completely self-contained mobile pulmon-
ary unit was designed to be housed in a
27-ft Winnebago van and is fully operational.
Complete studies of pulmonary function per-
formed at the plant site include measurements
of lung volume and compartments, maximum
expiratory flow rates, ventilatory distribution,
including closing volume, and pulmonary diffus-
ing capacity. These measurements will be per-
formed on a yearly basis and compared with
the pre-exposure determinations. In addition,
ventilatory function measurements are being
performed every 4 months in order to provide
early detection of any change in airways func-
tion. Recordings of both volume plotted against
time (conventional spirometry) and maximum
expiratory flow volume curves are being ob-
tained with a separate but identical electronic
spirometer, digitizing system, and rapidly re-
sponding X-Y recorder which is housed per-
manently at the plant site.
The population under investigation consists
of three groups: workers engaged in produc-
tion of TDI and who are more or less continu-
ously at risk of TDI exposure (83), mainte-
nance workers who have intermittent exposure
to TDI (28), and employees of other chemical
facilities within the complex who are pre-
sumed to have little or no TDI exposure and
who serve as "controls" (55). The total study
population of 166 was studied prior to start-up
of TDI production and has been followed by
clinical, pulmonary physiologic, and immuno-
logic methods since the beginning of exposure.
Methods of Biologic Monitoring
Clinical
An initial questionnaire was administered
by a trained interviewer using the National
Heart and Lung Institute modification of the
British MRC questionnaire with the addition
of several questions adopted for this study.
A follow-up questionnaire was designed by the
investigators to detect change in respiratory
health with the detection of any new or more
prominent respiratory symptoms which may
be associated with exposure at work.
Immunologic
In April-May 1973, prior to commencement
of TDI production, a visit was made to the
plant to collect pre-exposure blood samples for
eosinophil counts, immunoglobulin levels, and
antibody assays, and to perform skin tests with
common inhalant allergens and TDI-human
serum albumin conjugates. A second visit was
made in November-December, 1973, when blood
samples were again collected following com-
mencement of TDI production.
Serum was separated from the blood samples
at the plant, frozen, and stored at -70°C until
used to quantitate immunoglobulin levels (IgG,
IgA, IgM, IgD, IgE), perform guinea pig PCA
and monkey P-K tests, and detect anti-TDI
antibodies by the radioimmunoassay and pas-
sive hemagglutination techniques.
Conjugation of TDI to Serum Albumin:
TDI was conjugated to human and bovine serum
albumin. In an ice bath, 100 ml of a 1%o solu-
tion of the protein in 0.85% sodium chloride
was adjusted to pH 8.5 with 1N NaOH. To this,
100 ml of 20 mg-%0 TDI in dioxane was added
slowly over a 3-hr period, maintaining pH at
8.5 with 1N NaOH. The mixture was left in
the ice bath for 1 hr and then transferred to a
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103dialysis bag and left in the hood overnight to
allow dioxane to evaporate. Following dialysis
in the cold against six changes of phosphate-
buffered saline (pH 7.4), the conjugate was
lyophilized and stored at -20°C until used.
Conjugation was confirmed by ultraviolet ab-
sorption at 245 nm.
Skin Testing: A standard prick test was
employed for immediate wheal and erythema
responses. The common inhalant allergens used
were Aspergillus sp., Bermuda grass, house
dust, Alternraria sp., giant ragweed, pecan, oak,
and plantain in 1:20 (w/v) concentration. For
skin testing with TDI, 0.02 ml of a 5 mg per
ml solution of HSA-TDI in saline was injected
intradermally and the injection site observed
for 30 min.
Eosinophil Counts: Eosinophils were count-
ed in a Fuchs-Rosenthal counting chamber
using a saponin-eosin stain and levels expressed
as number of cells per cubic millimeter.
Immunoglobulin Quantitation: Immuno-
globulins G, A, M, and D were quantitated by
the single radial diffusion technique (1). IgE
was quantitated by the radioimmunoassay tech-
nique described previously (2).
Anti-TDI Antibody Quantitation: Circu-
lating anti-TDI antibodies were assayed for
by two methods: radioimmunoassay by use of
Sephadex G-25 superfine to which HSA-TDI
antigen had been conjugated (2), and passive
hemagglutination assay by use of sheep red
blood cells to which HSA-TDI antigen had been
conjugated by tannic acid (3),
In Vivo Testing for Homocytotropic and
Heterocytotropic Anti-TDI Antibodies: Sera
were tested for heterocytotropic anti-TDI anti-
bodies by the passive cutaneous anaphylaxis
technique (PCA) in guinea pigs (4) and for
homocytotropic anti-TDI antibodies by the
Prausnitz-Ktistner method described by Layton
(5).
Cellular Studies
Lymphocyte transformation was measured
in selected individuals using a previously de-
scribed method (6); lymphocytes from 50-60
ml of heparinized blood were diluted to give
approximately 1 X 106 lymphocytes per tube.
To appropriate tubes, 0.1 ml of antigen con-
centrations as used by Avery et al. (7) (0.5,
0.05, and 0.005 mg TDI-HSA per ml) was
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FIGURE 3. Per cent of sampling periods with (*)
mean and (X) maximum TDI concentrations > 0.02
ppm (all locations).
added. Following incubation in a CO2 atmos-
phere 1 MCi (2 Ci/mmole) of thymidine was
added to each tube, incubated overnight, and
harvested. A trichloroacetic acid precipitate
was placed into scintillation cocktail contain-
ing toluene, 1,4-bis[2-(4-methyl)5-phenoxylox-
azoyl] benzene and 2,5-diphenyloxazole, and
counted on a liquid scintillation counter. Results
were recorded as DPM per tube.
Inhalation Challenge Testing
Selected workers who have apparently devel-
oped "clinical sensitivity" to TDI vapor expo-
sure have been brought to the laboratory in
order that carefully controlled and monitored
exposure to TDI can be combined with repeated
measurements of any adverse biologic response.
After initial baseline evaluation, exposure was
limited to 15 min, and in no case did the TDI
atmospheric concentration exceed the threshold
limit value (TLV) of 0.02 ppm. The worker
was followed with appropriate monitoring until
recovery from any adverse response.
Results
Environmental
The proportion of 15 min sampling periods
in which the mean or maximum TDI concen-
trations exceeded the TLV of 0.02 ppm is
shown (Fig. 3) and indicates frequent excur-
sions above this present ceiling value. These
Environmental Health Perspectives 104Table 1. TDI mean and maximum concentrations in %
of samples >0.02 ppm and (average in ppm) by plant
location and time of operation.
Before 11/1/73 After 11/1/73
(start-up) (on-line)
Location
Mean Maxi- Mean Maxi-
mum mum
TDI synthesis 3.2% 6% 15.1% 19.3%
(0.0056) (0.0071) (0.0113) (0.0138)
Finishing 30.4% 33.3% 27% 33.3%
(0.0173) (0.0205) (0.0164) (0.0211)
Drumming 13.5% 16.1% 8.4% 9.6%
(0.011) (0.0129) (0.0075) (0.0088)
All 21.2% 24.3% 14.5% 17.5%
(0.0136) (0.0165) (0.0106) (0.013)
Avg Sa Oct Dec .b. Feb Mscb ApcI may Jo"
FIGURE 4. Average weekly maximum TDI concentra-
tion (by location): (. . .) TDI synthesis; (-)
finishing and TDI pump-out; (--) drumming.
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FIGURE 5. Per cent of days with average concentra-
tion TDI > 0.005 ppm (all locations).
excursions have occurred during the start-up,
and have continued since the plant has been
on line. The proportion of sampling periods
with excessive concentrations has diminished
overall since start-up was completed (Table 1),
primarily because of improvement in the level
of exposures in the drumming area. That all
major locations have participated in excursions
above the TLV can be appreciated by review
of Figure 4. In view of the recently published
NIOSH Criteria Document recommending an
8-hr time-weighted average of 0.005 ppm as
the TDI standard, the proportions of days
where the mean concentrations of TDI ex-
ceeded this level was plotted by month for the
plant as a whole. Although there was some
monthly variation, in general the average TDI
concentration exceeded the new recommended
standard on approximately half of the days
(Fig. 5). Considerable effort by the plant per-
sonnel is continuing in order that TDI expo-
sures can be minimized so that average con-
centrations will be reduced.
Biologic Response
Clinical, physiologic, and immunologic data
are markedly limited, since at the time of this
report, the first full year of exposure has not
yet elapsed. As of this time, a number of
workers have presented with acute respiratory
symptoms, generally short-lived, resulting from
a single exposure to an irritant gas or vapor,
usually phosgene or TDI. Most workers can
accurately report which exposure had occurred,
and often there is an associated recognizable
malfunction as the source of his exposure. Ten
to twelve workers appear to have become "clini-
cally sensitive" to TDI vapor with such recur-
rent respiratory symptoms as cough, shortness
of breath, chest tightness, and wheezing occur-
ring after what seems to them to be minimal
exposure to this vapor. These symptoms may
have followed a heavy exposure to TDI initially
but in some instances such a single episode
did not seem to occur. These individuals have
been removed from the TDI area to another
part of the chemical manufacturing complex
but not always without continuation of some
of their respiratory complaints. The affected
workers demonstrated a definite pattern of air
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FIGURE 6. Inhalation challenge test: (0) FEV (1
sec); (0) FEF (25-75%). TDI = 0.0087 ppm. See
text for details.
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FIGURE 7. Inhalation challenge test: (0) FEV (1
sec); (0) FEF (25-75%). TDI = p.0087 ppm. See
text for details.
flow obstruction in association with their
symptoms.
Inhalation challenge tests to TDI produced
a variety of patterns in those clinically sen-
sitized workers studied to date. A reduction in
ventilatory function may occur both immedi-
ately following exposure and again several
hours later, this late response being quite vari-
able in degree and time required for recovery,
the latter at times being longer than 24 hr. The
characteristic dual response is shown in Figure
6. Another worker exhibited only a slight
immediate reduction in ventilatory function
2 3 4
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FIGURE 9. Inhalation challenge test: FEF (25-75%):
(0) TDI = 0.0102 ppm; (0) TDI = 0.0028 ppm.
See text for details.
and also demonstrated the greater sensitivity
of the forced expiratory flow, 25-75%, in con-
trast to the more commonly measured forced
expiratory volume, 1 sec (Fig. 7). The imme-
ditate response may be absent entirely, with
only a late response demonstrated following
exposure (Fig. 8). It is obvious that in the
plant setting, associating occupational exposure
with respiratory symptoms may provide some
difficulty in such an individual with a result-
ing delay in diagnosis. A dose-response rela-
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106tionship in a positive challenge test does not
appear to have been previously demonstrated
for TDI. In this study, a few individuals have
failed to develop airways obstruction at one
level of TDI but demonstrate the characteristic
dual response at a higher level (Fig. 9). These
early results do not yet establish the threshold
level for TDI exposure, below which an adverse
response will not occur, but hopefully addi-
tional data will be helpful in realizing this aim.
Information concerning a possible general
long-term adverse effect of TDI on respiratory
health must await at least the follow-up studies
after one full year of exposure; definitive
conclusions will not be possible until the
completion of this multiyear investigation.
Additionally, only preliminary data is avail-
able regarding host factors and mechanism of
action associated with TDI respiratory effects.
On skin testing, 36%o of group 1, 7% of
group II, and 24%o of group III subjects re-
acted to more than one of the eight inhalant
allergens employed, indicating that each of
the study groups contained atopic individuals.
Positive reactions to HSA-TDI conjugate were
observed in four subjects; however, testing
with HSA alone gave similar reactions to those
obtained with the HSA-TDI conjugate in
each case, indicating lack of TDI specificity.
Immunoglobulin quantitations showed a similar
distribution for each group with no significant
difference in mean values (Table I). Post-
exposure samples showed no significant group
difference with the exception of an unexpected
increase of IgE levels in the nonexposure group
from a mean value of 114.2 ng/ml to 635.3
ng/ml. Total eosinophil counts showed a similar
distribution both before and after exposure,
and there were no significant group differences.
PCA and P-K tests, performed with all post-
exposure visit serum samples, were uniformly
negative. The validity of these tests is not con-
firmed, however, due to a lack of known P-K
and PCA positive control sera.
Passive hemagglutination and radiommuno-
assay (RIA) tests for specific TDI antibodies
were negative in all study subjects. Although
some sera yielded counts higher than back-
ground in the RIA, these were not sufficiently
high to be considered definite positives (5 2
times background). RIA controls using serum
from two rabbits immunized with TDI in com-
plete Freud's adjuvant were positive, and tests
with increasing amounts of these sera showed
a linear relationship with counts per minute.
Absorption studies indicated that the RIA
technique was specific for anti-TDI antibodies.
Lymphocyte transformation tests were per-
formed on four subjects who were "sensitized"
to TDI and exhibited positive provocative
bronchial challenge responses with aerosolized
TDI in a controlled environment. No TDI-HSA-
induced lymphocyte transformation was ob-
tained above control values with any of the
antigen concentrations employed; however,
good stimulation was obtained with phyto-
hemagglutinin in all subjects.
Comments
At the time of this preliminary report, a
limited number of observations seem appropri-
ate; the major body of information, which will
hopefully ultimately result from this investiga-
tion, is yet to come. It is apparent that during
the first year of operation in this plant signifi-
cant periodic exposures to TDI vapor have
occurred in a variety of operations; through
the use of continuous monitoring, atmospheric
TDI concentrations can be shown to exceed
periodically but regularly the present TLV.
Continuous area monitoring has added an
important new dimension to the study of TDI
respiratory health effects and the addition of
continuous personal air sampling in the near
future will provide even more valuable infor-
mation concerning the individual worker's ex-
posure to this vapor. The exposures to date
have produced episodes of acute irritant effects
with the appropriate respiratory symptoms,
and also resulted in "clinical sensitivity" in
several workers at current levels of TDI expo-
sure. Carefully controlled inhalation challenge
tests have provided confirmation of the adverse
respiratory effect in these individuals and have
demonstrated the varying patterns of response.
While susceptibility to the effects of TDI has
been suspected to be on an immunologic basis,
these preliminary results indicate that the sub-
jects tested to date, who worked in a TDI-
containing environment, did not reveal a detec-
table immunologic response to TDI under the
study conditions employed. Immunoglobulin
levels did not change significantly following the
start of TDI production with the exception of
a marked increase of IgE levels in group III.
The inability to detect IgE class-specific anti-
June 1975 107TDI antibodies during the early phase of study
may indicate that a critical time-dose relation-
ship exists between length and intensity of
exposure to TDI. A further possibility is that
TDI-induced bronchospasm may occur via a
nonimmunologic mechanism such as nonspecific
mediator release. It is obvious to both plant
personnel and the investigators that more effec-
tive control of TDI vapor in the plant environ-
ment must be accomplished.
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